MUVON Therapeutics CEO Deana Mohr was selected as one of ten Venture Leaders in Medtech to represent the Swiss National Startup Team in...

MUVON was featured in an article by Startupticker describing our regenerative approach for the treatment of incontinence and the progress...

MUVON is excited to have been selected as one of the top 10 startups in the Health and Nutrition vertical of the 2021 >>venture>> startup...

MUVON Therapeutics is proud to have been selected as one of 30 start-ups and projects from around the world to join Switzerlands first...

The University of Zurich (UZH) is advancing biotechnology with innovations. Thanks to a systematic support system and the dynamic...

MUVON Therapeutics is proud to announce the acceptance as a Wyss Zurich Project starting April 2021. The Wyss Zurich is a joint...

Abstract: Urinary incontinence affects a large number of patients, and the cost of treatment continues to rise with the demographic...

In October 2020 MUVON Therapeutics Ltd. was founded. The technology behind MUVON was developed over the past decade at the University of...

Abstract Muscle precursor cells (MPCs) are activated satellite cells capable of muscle fiber reconstruction. Therefore, autologous MPC...

Abstract Multiple modalities, including injectable bulking agents and surgery, have been used to treat stress urinary incontinence....

Abstract Muscle bioengineering is proposed as a treatment option for various conditions requiring restoration of muscle function. In...

Abstract Muscle precursor cells (MPCs) are activated satellite cells capable of muscle fiber reconstruction. Therefore, autologous MPC...

Abstract Autologous cell transplantation for the treatment of muscle damage is envisioned to involve the application of muscle precursor...

Abstract While many groups demonstrated new muscle tissue formation after muscle precursor cell (MPC) injection, the capacity of these...